XTRA:BAYNPharmaceuticals
Assessing Bayer (XTRA:BAYN) Valuation After Positive Asundexian Stroke Trial Results And Renewed Investor Interest
Bayer (XTRA:BAYN) is back in focus after reporting Phase III OCEANIC-STROKE data for its investigational Factor XIa inhibitor asundexian, showing a 26% reduction in recurrent ischemic strokes without a clear rise in major bleeding.
See our latest analysis for Bayer.
Those OCEANIC-STROKE results land at a time when Bayer’s share price has already been gathering pace, with a 30 day share price return of 10.36% and a 90 day share price return of 61.89%. Meanwhile, the 1 year total shareholder...